Evidence map›Paper›PMID 28328576›Full record

ArticlePain2017

Chronic pain patients' perspectives of medical cannabis.

Brian J Piper, Monica L Beals, Alexander T Abess, Stephanie D Nichols, Maurice W Martin, Catherine M Cobb, Rebecca M DeKeuster

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04729179 (Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial), which is not on this map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04729179 phase3completednot on this mapstarted 2021, after this paper: background citation

Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial

TypeinterventionalSponsorMarius HenriksenRan2021 to 2024Enrolled200ConditionsFibromyalgiaArmsCannabidiol, Placebo
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Cannabis for pain in orthopedics: a systematic review focusing on study methodologyCanadian journal of surgery. Journal canadien de chirurgie · 2019
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brian J PiperaDepartment of Basic Sciences, The Commonwealth Medical College, Scranton, PA, USA bDepartment of Psychological Sciences, Northern Arizona University, Flagstaff, AZ, USA cDepartment of Anesthesiology and Pain Management, Maine Health, Maine Medical Center, Portland, ME, USA dDepartment of Pharmacy Practice, Husson University School of Pharmacy, Bangor, ME, USA eDepartment of Community Health Education, University of Maine, Farmington, ME, USA fCenter for Wellness Leadership, Portland, ME, USA. R. M. DeKeuster is now with Calyx Concepts LLC, Sidney, ME, USA gWellness Connection of Maine, Gardiner, ME, USA.
Monica L Beals
Alexander T Abess
Stephanie D Nichols
Maurice W Martin
Catherine M Cobb
Rebecca M DeKeuster

Funding

MODE OF ACTION OF ENVIRONMENTAL TOXICANTST32ES007060 · NIEHS · OREGON STATE UNIVERSITY · PI Jamie DeWitt, Siva Kumar Kolluri · 1985 to 2026
$11.6M
NIEHS NIH HHS T32 ES007060
6 · The paper itself

Abstract

Medical cannabis (MC) is used for a variety of conditions including chronic pain. The goal of this report was to provide an in-depth qualitative exploration of patient perspectives on the strengths and limitations of MC. Members of MC dispensaries (N = 984) in New England including two-thirds with a history of chronic pain completed an online survey. In response to "How effective is medical cannabis in treating your symptoms or conditions?," with options of 0% "no relief" to 100% "complete relief," the average was 74.6% ± 0.6. The average amount spent on MC each year was $3064.47 ± 117.60, median = $2320.23, range = $52.14 to $52,140.00. Open-ended responses were coded into themes and subthemes. Analysis of answers to "What is it that you like most about MC?" (N = 2592 responses) identified 10 themes, including health benefits (36.0% of responses, eg, "Changes perception and experience of my chronic pain."), the product (14.2%, eg, "Knowing exactly what strain you are getting"), nonhealth benefits (14.1%), general considerations (10.3%), and medications (7.1%). Responses (N = 1678) to "What is it that you like least about MC?" identified 12 themes, including money (28.4%, eg, "The cost is expensive for someone on a fixed income"), effects (21.7%, eg, "The effects on my lungs"), the view of others (11.4%), access (8.2%), and method of administration (7.1%). These findings provide a patient-centered view on the advantages (eg, efficacy in pain treatment, reduced use of other medications) and disadvantages (eg, economic and stigma) of MC.

Indexed as

Health Knowledge, Attitudes, PracticeSocial StigmaChronic PainFemaleHumansMaleMedical MarijuanaMiddle AgedPain ManagementSurveys and QuestionnairesMedical Marijuana

Identifiers

PMID28328576
PMCPMC5845915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.